Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice

World Journal of Gastroenterology

Volumn 18, Issue 10, 2012, Pages 1059-1066

  Diao, Lei ^a   Mei, Qiao ^a   Xu, Jian Ming ^a   Liu, Xiao Chang ^a   Hu, Jing ^a   Jin, Juan ^a   Yao, Qiang ^a   Chen, Mo Li ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Intestinal mucosal permeability; Mitochondria; Non steroid anti inflammatory drugs; Oxidative damage; Rebamipide; Tight junction

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DICLOFENAC; MYELOPEROXIDASE; NITRATE REDUCTASE (NADH); REBAMIPIDE; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; INTESTINE MUCOSA PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; MOUSE; NONHUMAN; SMALL INTESTINE MUCOSA; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84863360000     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i10.1059     Document Type: Article

References (36)

1. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ. Blood and protein loss via smallintestinal inflammation induced by non-steroidal antiinflammatory drugs. Lancet 1987; 2: 711-714.
2. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847.
3. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-754.
4. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.
5. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-366.
6. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterol 1995; 108: 1566-1581.
7. Knowles RG. Nitric oxide biochemistry. Biochem Soc Trans 1997; 25: 895-901.
8. Teahon K, Smethurst P, MacPherson AJ, Levi J, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with an elemental diet. Eur J Gastroenterol Hepatol 1993; 5: 79-84.
9. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993; 104: 1627-1632.
10. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 1163-1169.
11. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341: 1437-1439.
12. Hiratsuka T, Futagami S, Shindo T, Hamamoto T, Ueki N, Suzuki K, Shinji Y, Kusunoki M, Shinoki K, Wada K, Miyake K, Gudis K, Tsukui T, Sakamoto C. Rebamipide reduces indomethacin-induced gastric injury in mice via downregulation of ICAM-1 expression. Dig Dis Sci 2005; 50 Suppl 1: S84-S89
13. Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Mégraud F. Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. Scand J Gastroenterol 2000; 35: 470-475.
14. Matysiak-Budnik T, Thomas-Collignon A, Mégraud F, Heyman M. Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide. Dig Dis Sci 2001; 46: 1558-1566.
15. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y. Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 2000; 45: 1608-1616.
16. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 2000; 95: 1838-183917.
17. Tugendreich S, Pearson CI, Sagartz J, Jarnagin K, Kolaja K. NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. Toxicol Pathol 2006; 34: 168-179.
18. Lange S, Delbro DS, Jennische E. Evans blue permeation of intestinal mucosa in the rat. Scand J Gastroenterol 1994; 29: 38-46.
19. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999; 48: 137-143.
20. Chen LW, Hsu CM, Cha MC, Chen JS, Chen SC. Changes in gut mucosal nitric oxide synthase (NOS) activity after thermal injury and its relation with barrier failure. Shock 1999; 11: 104-110.
21. Yang ZL, Yang LY, Huang GW, Liu HL. Tri-iodothyronine supplement protects gut barrier in septic rats. World J Gastroenterol 2003; 9: 347-350.
22. Wang Q, Fang CH, Hasselgren PO. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1013-R1023.
23. Johnson D, Lardy H. Isolation liver or kidney mitochondtia. Meth in Enzymol 1967; 10: 94-97.
24. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-353.
25. Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim Biophys Acta 1986; 850: 436-448.
26. Halestrap AP, Davidson AM. Inhibition of Ca2(+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 1990; 268: 153-160.
27. Minezaki KK, Suleiman MS, Chapman RA. Changes in mitochondrial function induced in isolated guinea-pig ventricular myocytes by calcium overload. J Physiol 1994; 476: 459-471.
28. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480-489.
29. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506-511.
30. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 1985; 290: 347-349.
31. Bjarnason I, Thjodleifsson B. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (Oxford) 1999; 38 Suppl 1: 24-32.
32. Banan A, Fitzpatrick L, Zhang Y, Keshavarzian A. OPCcompounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. Free Radic Biol Med 2001; 30: 287-298.
33. Murakami K, Okajima K, Uchiba M, Harada N, Johno M, Okabe H, Takatsuki K. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 1997; 42: 319-325.
34. Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, Chung IS. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 2007; 52: 1776-1782.
35. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H. Efficacy of rebamipide for diclofenacinduced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebocontrolled, cross-over study. J Gastroenterol 2008; 43: 270-276.
36. Nagano Y, Matsui H, Muramatsu M, Shimokawa O, Shibahara T, Yanaka A, Nakahara A, Matsuzaki Y, Tanaka N, Nakamura Y. Rebamipide significantly inhibits indomethacininduced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci 2005; 50 Suppl 1: S76-S83.